Search for content, post, videos

A Clinical Analysis of Liver and Renal Function Tests as Predictive Markers in Lung Adenocarcinoma

Department of Biology, College of Science, Salahaddin University-Erbil, 44002 Erbil, Kurdistan Region, Iraq
*(e-mail:; Mobile: 964 75042 06970)
(Received: April 2, 2023; Accepted: May 7, 2023)


The aim of this research study was to examine and test the prognostic value of liver and renal functions
as prospective prognostic markers in lung adenocarcinoma (LUAD). Serum was extracted from blood samples collected from 20 LUAD patients and 20 healthy controls for biochemical analysis of liver and renal function tests. In addition, 110 LUAD samples were examined for epidermal growth factor receptor (EGFR) mutations. Indicating liver injury, the results revealed significant differences between LUAD patients and healthy controls for Alkaline phosphatase (ALP), aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) levels. In addition, the concentrations of urea and creatinine were substantially higher in LUAD patients compared to healthy controls, indicating renal impairment. In addition, the rate of EGFR mutations was 40%, and there was a strong association between EGFR mutations and liver function tests. The study indicated that liver and renal function tests may serve as valuable prognostic markers for LUAD. If these tests could serve as reliable markers, clinicians might be able to identify patients with a high risk of adverse outcomes and modify treatment accordingly. In addition, the findings suggest that novel therapies that target hepatic and renal problems may improve patient outcomes.
Key words : LUAD patients, liver function test, renal function test